Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Imatinib Frontline Therapy Is Safe and Effective in Patients with Chronic Myeloid Leukemia (CML) with Liver and/or Renal Dysfunction.

Weigang Tong, M.D., Ph.D., Hagop Kantarjian, M.D., Susan O’Brien, M.D., Stefan Faderl, MD, Farhad Ravandi, MBBS, William G Wierda, M.D., Ph.D., Steven Kornblau, M.D., Gautam Borthakur, M.D., Guillermo Garcia-Manero, M.D., Elizabeth Burton, Mary Beth Rios, Jorge Cortes, M.D.

Blood (2008) 112 (11): 2126.

https://doi.org/10.1182/blood.V112.11.2126.2126

Published: 2008

Journal Articles

Antileukemia Activity of JNJ-26481585, a Potent Second-Generation Histone Deacetylase Inhibitor

Weigang Tong, M.D., Ph.D., Yue Wei, Ph.D., William Stevenson, M.D., Ph.D., Shao-Qing Kuang, M.D., Ph.D., Janine Arts, Ph.D., Guillermo Garcia-Manero, M.D.

Blood (2008) 112 (11): 2631.

https://doi.org/10.1182/blood.V112.11.2631.2631

Published: 2008

Journal Articles

Experience with the Combination of a Hypomethylating Agent and Valproic Acid in Pediatric Acute Myelogenous Leukemia

Michael Rytting, M.D., Patrick Zweidler-McKay, M.D., Ph.D., Yang Hui, Hagop Kantarjian, M.D., Guillermo Garcia-Manero, M.D.

Blood (2008) 112 (11): 4036.

https://doi.org/10.1182/blood.V112.11.4036.4036

Published: 2008

Journal Articles

Phase II Study of Lenalidomide and Prednisone for Patients with Myelofibrosis.

Alfonso Quintás-Cardama, MD, Ayalew Tefferi, M.D., Deborah Thomas, M.D., Jorge Cortes, M.D., Farhad Ravandi, M.D., Stefan Faderl, M.D., Guillermo Garcia-Manero, M.D., Gautam Borthakur, M.D., Neda Bell, M.D., Catriona Byrne, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D., Ph.D

Blood (2007) 110 (11): 3545.

https://doi.org/10.1182/blood.V110.11.3545.3545

Published: 2007

Journal Articles

Phase II Study of Dasatinib (SPRYCEL™) in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis.

Srdan Verstovsek, MD, PhD, Tefferi Ayalew, M.D., Cortes Jorge, M.D., Susan O’Brien, M.D., Guillermo Garcia-Manero, M.D., Animesh Pardanani, M.D., Cem Akin, M.D., Stefan Faderl, M.D., Deborah Thomas, M.D., Hagop Kantarjian, M.D.

Blood (2007) 110 (11): 3551.

https://doi.org/10.1182/blood.V110.11.3551.3551

Published: 2007

Journal Articles

Intensively Timed Induction (ITI) Chemotherapy in Adults with Acute Myelogenous Leukemia (AML).

Michael Rytting, MD, Srdan Verstovsek, M.D., Ph.D., Guillermo Garcia-Manero, M.D., Farhad Ravandi-Kashani, M.D., Sherry Pierce, R.N., Elihu Estey, M.D.

Blood (2007) 110 (11): 1851.

https://doi.org/10.1182/blood.V110.11.1851.1851

Published: 2007

Journal Articles

Pegylated Interferon-alfa-2a (PEG-IFN-α-2A; PEGASYS™) for Essential Thrombocythemia (ET) and Polycythemia Vera (PV): An Update of an Ongoing Phase II Study.

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Guillermo Garcia-Manero, M.D., Jorge Cortes, M.D., Marie Ann Richie, Gautam Borthakur, M.D., Srdan Verstovsek, M.D., Ph.D.

Blood (2007) 110 (11): 3542.

https://doi.org/10.1182/blood.V110.11.3542.3542

Published: 2007

Journal Articles

Phase II Study of CEP701, an Orally Available JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.

Srdan Verstovsek, MD, PhD, Ayalew Tefferi, M.D., Steven Kornblau, M.D., Deborah Thomas, M.D., Jorge Cortes, M.D., Farhad Ravandi-Kashani, M.D., Guillermo Garcia-Manero, M.D., Hagop Kantarjian, M.D.

Blood (2007) 110 (11): 3543.

https://doi.org/10.1182/blood.V110.11.3543.3543

Published: 2007

Journal Articles

Clinical Features and Prognosis of Patients with Myelodysplastic/Myeloproliferative Syndrome-Unclassified (MDS/MPD-U): Refractory Anemia with Ringed Sideroblasts with Thrombocytosis (RARS-T) Is a Favorable Prognostic Subgroup.

Ehab Atallah, MD, Hagop Kantarjian, M.D., Jorge Cortes, M.D., Sherry Pierce, R.N., Elihu Estey, M.D., Guillermo Garcia-Manero, M.D., Deborah Thomas, M.D., Farhad Ravandi-Kashani, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.,; PhD.

Blood (2006) 108 (11): 2612.

https://doi.org/10.1182/blood.V108.11.2612.2612

Published: 2006

Journal Articles

Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS).

Elias Jabbour, MD, Hagop M. Kantarjian, M.D., Jorge Cortes, M.D., William G. Wierda, M.D., Ph.D., Alessandra Ferrajoli, M.D., Stefan Faderl, M.D., Susan O’Brien, M.D., Farhad Ravandi-Kashani, M.D., Srdan Verstovsek, M.D., Ph.D., Guillermo Garcia-Manero, M.D., Jan Davisson, BS, ADN, Francis Giles, M.D., Jianqin Shan, Ph.D., Jean-Pierre Issa, M.D.

Blood (2006) 108 (11): 2652.

https://doi.org/10.1182/blood.V108.11.2652.2652

Published: 2006

Journal Articles

Characteristics and Outcomes of 38 Patients with Acute Myeloid Leukemia Evolving from Previous Well Characterized Myeloproliferative Disorder.

Constantine S. Tam, MD, Francis Giles, M.D., Jorge Cortes, M.D., Guillermo Garcia-Manero, M.D., Elihu Estey, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 2705.

https://doi.org/10.1182/blood.V108.11.2705.2705

Published: 2006

Journal Articles

A Phase II Study of Azacitidine (Vidaza™) for Patients with Myelofibrosis (MF).

Alfonso Quintas-Cardama, MD, Hagop Kantarjian, M.D., Guillermo Garcia-Manero, M.D., Deborah Thomas, M.D., STeven Kornblau, M.D., Elihu Estey, M.D., Marilyn Nemri, R.N., Jorge Cortes, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 2706.

https://doi.org/10.1182/blood.V108.11.2706.2706

Published: 2006

Journal Articles

PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study.

Elias Jabbour, MD, Hagop Kantarjian, M.D., Charles A. Koller, M.D., Stefan Faderl, M.D., Alessandra Ferrajoli, M.D., Mary Ann Richie, R.N., Guillermo Garcia-Manero, M.D., Jorge Cortes, M.D., Zeev Estrov, M.D., Farhad Ravandi-Kashani, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.

Blood (2006) 108 (11): 3636.

https://doi.org/10.1182/blood.V108.11.3636.3636

Published: 2006

Journal Articles

Effect of Failure To Respond to Targeted Therapy on Response to Cytotoxic Therapy in Pts Age ≥ 60 with Newly-Diagnosed AML.

Elihu H. Estey, MD, Guillermo Garcia-Manero, M.D., Francis Giles, M.D., Hagop M. Kantarjian, M.D.

Blood (2006) 108 (11): 1965.

https://doi.org/10.1182/blood.V108.11.1965.1965

Published: 2006

Journal Articles

Prognostic Significance of β-2 Microglobulin Levels in Acute Myeloid Leukemia: Analysis of 1293 Patients.

Apostolia-Maria Tsimberidou, MD, PhD, Hagop M. Kantarjian, M.D., Michael J. Keating, M.D., Susan O’Brien, M.D., Sijin Wen, M.S., Jorge Cortes, M.D., Francis Giles, M.D., Charles Asa Koller, M.D., Guillermo Garcia-Manero, M.D., Sherry Pierce, B.S.N., Mark Brandt, Emil J. Freireich, M.D., Elihu H. Estey, M.D.

Blood (2006) 108 (11): 802.

https://doi.org/10.1182/blood.V108.11.802.802

Published: 2006

Journal Articles

Hypomethylation Dynamics Following Decitabine Therapy in Chronic Myelogenous Leukemia.

Jean-Pierre J. Issa, M.D., Vazganush Gharibyan, Ph.D., Jaroslav Jelinek, M.D., Ph.D., Gail Morris, RN, Srdan Verstovsek, M.D., Moshe Talpaz, M.D., Guillermo Garcia-Manero, M.D., Hagop M. Kantarjian, M.D.

Blood (2004) 104 (11): 2956.

https://doi.org/10.1182/blood.V104.11.2956.2956

Published: 2004

Journal Articles

Intracranial Hemorrhage (ICH) in Patients (pts) with Newly Diagnosed Leukemia: Incidence and Effect on Outcome.

Yasuhiro Oki, M.D., Elias Jabbour, M.D., Hagop Kantarjian, M.D., Elihu Estey, M.D., Jorge E. Cortes, M.D., Stefan Faderl, M.D., Sherry Pierce, RN, BSN, BA, Xian Zhou, MS, BS, B. Nebiyou Bekele, Ph.D., Guillermo Garcia-Manero, M.D.

Blood (2004) 104 (11): 4530.

https://doi.org/10.1182/blood.V104.11.4530.4530

Published: 2004

Journal Articles

2 Chlorodeoxyadenosine (2-CdA) and Cytarabine (ara-C) Combination Is Effective and Safe in Idiopathic Hypereosinophilic Syndrome (HES).

Elias Jabbour, M.D., Srdan Verstovsek, M.D., Ph.D., Varsha Gandhi, Ph.D., M.S., B.S., Jorge Cortes, M.D., Francis Giles, M.D., Charles Koller, M.D., Susan O’Brien, M.D., William Plunkett, Ph.D., Guillermo Garcia-Manero, M.D., Ellen Jackson, Hagop Kantarjian, M.D., Michael Andreeff, M.D., Ph.D.

Blood (2004) 104 (11): 4764.

https://doi.org/10.1182/blood.V104.11.4764.4764

Published: 2004

Journal Articles

Detection of Aberrant DNA Methylation in Acute Lymphocytic Leukemia (ALL) Using a Real-Time Polymerase Chain Reaction (PCR) Assay.

Koyu Hoshino, M.D., Hui Yang, M.D., Blanca Sanchez-Gonzalez, M.D., Guillermo Garcia-Manero, M.D.

Blood (2004) 104 (11): 998.

https://doi.org/10.1182/blood.V104.11.998.998

Published: 2004

Journal Articles

PEG-Intron for Myeloproliferative Diseases: An Update of Ongoing Phase II Study.

Srdan Verstovsek, M.D., Ph.D., Kristie Lawhorn, BCLS, R.N., Francis Giles, M.D., Jorge Cortes, M.D., Deborah Thomas, M.D., Guillermo Garcia-Manero, M.D., Alessandra Ferrajoli, M.D., Stefan Faderl, M.D., Miloslav Beran, M.D., Ph.D., Moshe Talpaz, M.D., Hagop Kantarjian, M.D.

Blood (2004) 104 (11): 1517.

https://doi.org/10.1182/blood.V104.11.1517.1517

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Imatinib Frontline Therapy Is Safe and Effective in Patients with Chronic Myeloid Leukemia (CML) with Liver and/or Renal Dysfunction.

Antileukemia Activity of JNJ-26481585, a Potent Second-Generation Histone Deacetylase Inhibitor

Experience with the Combination of a Hypomethylating Agent and Valproic Acid in Pediatric Acute Myelogenous Leukemia

Phase II Study of Lenalidomide and Prednisone for Patients with Myelofibrosis.

Phase II Study of Dasatinib (SPRYCEL™) in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis.

Intensively Timed Induction (ITI) Chemotherapy in Adults with Acute Myelogenous Leukemia (AML).

Pegylated Interferon-alfa-2a (PEG-IFN-α-2A; PEGASYS™) for Essential Thrombocythemia (ET) and Polycythemia Vera (PV): An Update of an Ongoing Phase II Study.

Phase II Study of CEP701, an Orally Available JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.

Clinical Features and Prognosis of Patients with Myelodysplastic/Myeloproliferative Syndrome-Unclassified (MDS/MPD-U): Refractory Anemia with Ringed Sideroblasts with Thrombocytosis (RARS-T) Is a Favorable Prognostic Subgroup.

Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS).

Characteristics and Outcomes of 38 Patients with Acute Myeloid Leukemia Evolving from Previous Well Characterized Myeloproliferative Disorder.

A Phase II Study of Azacitidine (Vidaza™) for Patients with Myelofibrosis (MF).

PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study.

Effect of Failure To Respond to Targeted Therapy on Response to Cytotoxic Therapy in Pts Age ≥ 60 with Newly-Diagnosed AML.

Prognostic Significance of β-2 Microglobulin Levels in Acute Myeloid Leukemia: Analysis of 1293 Patients.

Hypomethylation Dynamics Following Decitabine Therapy in Chronic Myelogenous Leukemia.

Intracranial Hemorrhage (ICH) in Patients (pts) with Newly Diagnosed Leukemia: Incidence and Effect on Outcome.

2 Chlorodeoxyadenosine (2-CdA) and Cytarabine (ara-C) Combination Is Effective and Safe in Idiopathic Hypereosinophilic Syndrome (HES).

Detection of Aberrant DNA Methylation in Acute Lymphocytic Leukemia (ALL) Using a Real-Time Polymerase Chain Reaction (PCR) Assay.

PEG-Intron for Myeloproliferative Diseases: An Update of Ongoing Phase II Study.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only